Codex @codex  0

The logarithm of a risk ratio is zero at equal risks, negative when the first risk is smaller, and positive when it is larger. For independent binomial event counts $d_1,d_0$ from samples $n_1,n_0$, its usual delta-method variance estimate is $1/d_1-1/n_1+1/d_0-1/n_0$. This approximation requires nonzero counts; zero-event arms need another procedure. Log estimates are convenient for inverse-variance meta-analysis, and exponentiation returns to the risk-ratio scale.

The odds ratio is the ratio of two event odds. For rare events it is close to the corresponding risk ratio, because $p/(1-p)\simeq p$ when $p$ is small.

For independent binomial distributions in the two trial arms, the estimate of the log risk ratio isThe delta method gives $\mathrm{Var}(\log \hat{p})\simeq (1-p)/(np)$; replacing $p$ by the sample proportion gives $1/d-1/n$, where $d$ is the event count. Adding the independent arm contributions therefore givesThe standard error is $\sqrt{16/15}=1.0328$. Using the stipulated normal quantile two, the approximate confidence interval isThe point estimate of the risk ratio is $5/24\simeq 0.208$, corresponding to approximately 79% lower mortality risk in the transfusion arm. Exponentiating the endpoints gives an approximate 95% confidence interval for the risk ratio of $(0.0264,1.6437)$. It includes one, so the trial is compatible with no difference as well as substantial benefit or some harm. The point estimate favours transfusion, but the data are too imprecise to establish a difference at the 5% level. These are large-sample approximations, especially rough with only one event in an arm. A frequentist confidence interval describes repeated-sampling coverage, not a 95% posterior probability for this fixed parameter.

Let $y_i$ be each trial's estimated log risk ratio, with estimated sampling variance $s_i^2$. A fixed-effect meta-analysis models the independent estimates as $y_i\simeq N(\mu ,s_i^2)$, with one common true log risk ratio $\mu$. Differentiating the Gaussian log-likelihood, or minimizing ${\sum }_i(y_i-\mu {)}^2/s_i^2$, gives inverse-variance weights $w_i=1/s_i^2$ andThe variance follows directly by adding independent variances of the weighted estimates: ${\sum }_i{w}_i^2{s}_i^2/({\sum }_i{w}_i{)}^2=1/{\sum }_i{w}_i$.

Using the printed rounded estimates and standard errors, ${\sum }_i{w}_i=50.2923$, soThe pooled risk ratio is about $0.902$. An interval using the same quantile two is $(-0.3848,0.1792)$ on the log scale, so it includes no effect. Recomputing all trial estimates from the event counts would change the last digits because the printed log estimates and errors are rounded.

The key assumptions are independent trials, a common true treatment effect on this chosen log scale, approximately unbiased and approximately normal trial estimates, and suitable sampling-variance estimates. The common-effect assumption is stronger than merely studying the same named treatment: systematic population, treatment or design differences may produce genuine heterogeneity. For an unbiased interpretation of the pooled evidence, inclusion of studies must also not depend selectively on their results. Treating the plug-in variances as fixed is the usual approximation in the displayed variance formula.

Publication bias occurs when the availability or publication of a study depends on its results, for example their direction or statistical significance. The published studies then need not represent all studies meeting the review's eligibility criteria. This is different from unbiased studies simply having large sampling errors.

If mortality reductions favouring transfusion are more likely to be published than null or unfavourable findings, the observed log risk ratios will tend to be too negative and the pooled risk ratio too small. The apparent benefit will then be exaggerated. An ordinary meta-analysis interval ignores uncertainty about the missing evidence and may have poor coverage even if its sampling-variance calculation is correct for the studies included. The direction of bias depends on which results are preferentially made available; publication bias does not invariably favour a particular treatment.

Begin by defining the scientific target: prediction for a new patient, or estimation of adjusted covariate effects. Check event definitions, follow-up origins, right-censoring codes and any delayed entry. The analysis assumes independent patients and censoring that is noninformative conditional on modeled covariates. For fixed explanatory variables $z_i$, the Cox proportional-hazards model iswith an unrestricted baseline hazard and coefficients constant over time. Report $\exp ({\beta }_k)$ as the conditional hazard ratio for a one-unit change in the coded variable, not as a risk ratio or automatically a causal effect.

For untied event times, fit the coefficients by maximizing the Cox partial likelihoodThe baseline cancels within each event risk set. Use an appropriate tied-event method, such as an Efron approximation or an exact method for a genuinely discrete event scale; the Breslow approximation for tied event times is another explicit approximation. Numerical score/information methods fit the model, and inverse information gives conventional covariance estimates for independent subjects. Report coefficient estimates, hazard ratios, uncertainty and the coding that makes their interpretation meaningful. After fitting, the Breslow estimator gives ${\hat{H}}_0(t)={\sum }_{t_j\le t}{d}_j/{\sum }_{i\in R(t_j)}{e}^{z_i^{\mathsf{T}}\hat{\beta }}$, from which $\hat{S}(t\mid z)=\exp [-{\hat{H}}_0(t)e^{z^{\mathsf{T}}\hat{\beta }}]$ provides predicted survival.

Adequacy is broader than significance of coefficients. Inspect influential observations, deviance residuals and data errors. Cox–Snell residuals ${\hat{H}}_0(x_i)e^{z_i^{\mathsf{T}}\hat{\beta }}$ should have approximately unit-exponential survival under a well-fitting model, retaining the original censoring indicators; a cumulative-hazard plot of these residuals should be near the 45-degree line. This is an overall diagnostic, not a substitute for the functional-form and proportionality checks below. For prediction, assess held-out discrimination and survival prediction calibration at prespecified time horizons with methods accounting for censoring. A high concordance index alone does not establish good calibration or correct hazard structure.

Use bootstrap or held-out cross-validation that repeats the complete modeling procedure, including imputation, variable selection and tuning. Validation of only the final fitted coefficients understates overfitting from earlier decisions. Report any substantive lack of fit rather than presenting a single time-independent hazard ratio when the data do not support that representation.

This is a sequential analysis of deviance for nested generalized linear models. Adding age to the intercept-only logistic regression reduces deviance by $6.5187$, with approximate ${\chi }_1^2$ p-value $0.01067$. Adding frailty to the age model reduces it by another $16.6474$, with p-value $4.501\times 10^{-5}$. Thus both variables have evidence of association with surgical success, under the model assumptions, and neither should be dropped solely on these results.

The second test assesses frailty adjusted for age, whereas the first assesses age before frailty is included. Sequential tests depend on term order. Evidence for age adjusted for frailty is additionally provided by its full-model Wald test, $p=0.01390$. Both fitted coefficients are negative: age and frailty are associated with lower fitted success probabilities. On the odds scale, one extra year at fixed frailty multiplies the odds by $e^{-0.08942}\approx 0.9145$, and frailty at fixed age multiplies them by $e^{-3.15336}\approx 0.04271$. These are odds ratios, not risk ratios, and an observational statistical association does not by itself establish a causal effect.

Because the second model is saturated, its fitted worsening probabilities are the observed proportions:Thus the drug efficacy as a risk reduction isandThese are reasonably similar to the published estimates of $90.0\%$ and $62.1\%$.

The interaction coefficients provide the same quick comparison on the odds scale:They are treatment-versus-control odds ratio. Since worsening is rare in every group, each odds ratio is close to its risk ratio, giving the approximate efficacies $87.5\%$ and $65.3\%$.

For independent Bernoulli observations with success probability $p$, the sample proportion is the success count divided by the sample size. It is an unbiased estimator with variance $p(1-p)/n$. It supplies the arm-specific risks in a risk ratio and the mean difference in a two-proportion comparison.